Wellstar International update on the Duke Study for predicting nosocomial pressure ulcers

John Antonio, CEO of Wellstar International, Inc. (OTCBB:WLSI), today issued the following statement:

As the CEO of Wellstar, I wanted to take the time to update all of our shareholders with the current status of the company, as well as the direction of where the company is headed.

First and foremost are the Duke Study results. The study was designed to determine that long-wave infrared imaging can be used to identify skin temperature changes associated with underlying tissue changes. We wanted to determine if the use of Long Wave infrared imaging is as effective as the Braden Score in predicting nosocomial pressure ulcers.

As the study has been completed for sometime, the results were put on hold for non-payment. In December 2008, Wellstar was able to make the payment that was due to Duke University. Since that time, we have been awaiting the final report. While the company was late making their payment, Wellstar lost their position of expedience with the final results. Since the payment has been made, we believe there have been great strides in the last few months in compiling the data and putting the data into a final report. Wellstar has received several of the drafts pertaining to the final report for publishing. Wellstar believes that the final results of the study will be published within the next 30 to 60 days.

With the publication of the study, Wellstar intends to raise enough capital to be able to run a minimum of two trials within the marketplace. We cannot provide any guarantee that we will be able to successfully raise capital, or if we do raise capital, that it will be on acceptable terms. These two trials will run simultaneously and allow for Wellstar to work out the installation and execution process of our system. It is anticipated that the trials will be for a period of between 90 and 120 days.

While the trials are being held, Wellstar will begin marketing its system. We will focus our efforts on hospitals, nursing homes and long term facilities.

Another issue that I would like to address is the current volume of shares that are being traded. The high volumes of shares that are and have been selling are the result of our debt holder’s ability to convert into shares of common stock. Our promissory notes allow for the note holder to convert the outstanding principal and interest due to them into shares of common stock, which shares may be issued without a restrictive legend as the shares tack to the date of the issuance of the promissory notes under Rule 144. By the note holders converting to shares and selling into the marketplace, the company is reducing its debt. Until the company is cash flowing and able to meet it’s obligation to the note holders as well as its overhead, the conversions will continue.

Wellstar will be making announcements to the public as they achieve any significant progress in the process of rollout and installation of their systems.

Source:

Wellstar International, Inc

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Bruker Introduces Innovative Neuroscience Research Solution with High-Speed OptoVolt Voltage Imaging